Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugene Oh

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
European Urology Open Science|April 17, 2026
Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing RegistrySteven M Monda, Eugene Oh, Patrick J Lewicki, et al.
Elife|May 17, 2022
Integrative analysis of scRNA-seq and scATAC-seq revealed transit-amplifying thymic epithelial cells expressing autoimmune regulatorTakahisa Miyao, Maki Miyauchi, S Thomas Kelly, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 6, 2025
The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasisJoanna A Vuille, Cem Tanriover, Ezgi Antmen, et al.
Nature Communications|June 28, 2019
Noncoding dsRNA induces retinoic acid synthesis to stimulate hair follicle regeneration via TLR3Dongwon Kim, Ruosi Chen, Mary Sheu, et al.
Urologic Oncology|October 28, 2025
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE studyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
European Urology|September 15, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE StudyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
International Forum of Allergy & Rhinology|March 14, 2026
Determining the Minimal Clinically Important Difference of the 40-Item Smell Identification Test in People With Cystic FibrosisEugene Oh, Jessa E Miller, Michelle J Lee, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
European Urology Open Science|April 17, 2026
Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing RegistrySteven M Monda, Eugene Oh, Patrick J Lewicki, et al.
Elife|May 17, 2022
Integrative analysis of scRNA-seq and scATAC-seq revealed transit-amplifying thymic epithelial cells expressing autoimmune regulatorTakahisa Miyao, Maki Miyauchi, S Thomas Kelly, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 6, 2025
The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasisJoanna A Vuille, Cem Tanriover, Ezgi Antmen, et al.
Nature Communications|June 28, 2019
Noncoding dsRNA induces retinoic acid synthesis to stimulate hair follicle regeneration via TLR3Dongwon Kim, Ruosi Chen, Mary Sheu, et al.
Urologic Oncology|October 28, 2025
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE studyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
European Urology|September 15, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE StudyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
International Forum of Allergy & Rhinology|March 14, 2026
Determining the Minimal Clinically Important Difference of the 40-Item Smell Identification Test in People With Cystic FibrosisEugene Oh, Jessa E Miller, Michelle J Lee, et al.
Pageof 7